449 related articles for article (PubMed ID: 30093246)
1. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
Teitel JM
Transfus Apher Sci; 2018 Aug; 57(4):466-471. PubMed ID: 30093246
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Schmidt ML; Gamerman S; Smith HE; Scott JP; DiMichele DM
Am J Hematol; 1994 Sep; 47(1):36-40. PubMed ID: 8042614
[TBL] [Abstract][Full Text] [Related]
3. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
7. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
11. The Use of Bypassing Treatment Strategies in Hemophilia and Their Effect on Laboratory Testing.
Pruthi RK; Chen D
Semin Thromb Hemost; 2023 Sep; 49(6):651-660. PubMed ID: 37146647
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
Zhou ZY; Hay JW
Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
[TBL] [Abstract][Full Text] [Related]
13. Emicizumab for the treatment of haemophilia A: a narrative review.
Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
[TBL] [Abstract][Full Text] [Related]
14. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
15. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
16. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
17. Utilization of emicizumab in acquired hemophilia A: A case report.
Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
20. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
